Fulcrum Therapeutics, Inc.
FULC
$7.63
-$0.02-0.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 10.08% | -3.11% | |||
| Gross Profit | -10.08% | 3.11% | |||
| SG&A Expenses | 10.75% | -2.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.31% | -2.88% | |||
| Operating Income | -10.31% | 2.88% | |||
| Income Before Tax | -13.29% | 2.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.29% | 2.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.29% | 2.03% | |||
| EBIT | -10.31% | 2.88% | |||
| EBITDA | -10.48% | 2.89% | |||
| EPS Basic | -13.20% | 2.16% | |||
| Normalized Basic EPS | -13.19% | 2.15% | |||
| EPS Diluted | -11.79% | 0.92% | |||
| Normalized Diluted EPS | -13.19% | 2.15% | |||
| Average Basic Shares Outstanding | 0.08% | 0.10% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||